CPAx: Responsiveness and Minimal Clinically Important Difference
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · May 13, 2024
Trial Information
Current as of February 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, known as the CPAx study, is looking at a tool called the Chelsea Critical Care Physical Assessment tool (CPAx) to help measure how well critically ill patients are doing physically, especially when they are at risk of muscle weakness. Many patients in intensive care units (ICUs) can develop weakness that affects their recovery, and understanding how to track changes in their physical ability over time is important. The study aims to see how well the CPAx can show improvements as patients recover from critical illnesses and to determine a specific amount of change that would be meaningful for patients and their families.
To participate in this trial, individuals need to be at least 18 years old, have been on a breathing machine for at least 72 hours, and are expected to stay in the ICU for at least another 48 hours. Participants will receive standard physiotherapy care, and their progress will be tracked without any extra tests or burdens placed on them. The findings from this study could help improve treatment for muscle weakness in ICU patients and support healthcare providers in delivering better care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Mechanical ventilation ≥ 72 hours
- • Expected to remain for ≥ 48 hours in the ICU
- • Physiotherapy referral
- Exclusion Criteria:
- • Not expected to survive to hospital discharge (imminent to death)
- • Second or subsequent ICU admission for this hospital stay
- • Transfer from external ICU (with an ICU stay of \>72 hours)
- • Primary neurological admission diagnosis (i.e., of the central nervous system including stroke, intracerebral haemorrhage, traumatic brain injury)
- • Known pregnancy
- • Living in a care facility pre-admission (severe pre-existing mental or physical disability)
- • Local regulations (i.e. Switzerland: refusal of general consent)
Trial Officials
Sabrina Eggmann, PhD
Principal Investigator
Inselspital, Bern University Hospital, Switzerland; Monash University, Australia
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Clayton, , Australia
Melbourne, , Australia
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0